Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

SDX-308, a Structural Analog of Etodolac, Inhibits NF-κB Activity Resulting in Significant Inhibition of Osteoclast Formation/Activity and Multiple Myeloma Cell Growth.

Rentian Feng, PhD, Gulsum Anderson, PhD, Guozhi Xiao, MD, PhD, Gary Elliott, PhD, Lorenzo M. Leoni, MD, Markus Y. Mapara, MD, PhD, David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2006) 108 (11): 3456.

https://doi.org/10.1182/blood.V108.11.3456.3456

Published: 2006

Journal Articles

Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101 Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of Multiple Myeloma Growth In Vitro and In Vivo .

Rentian Feng, PhD, Ana B. Oton, MD, Kenneth Patrene, Gulsum Anderson, PhD, Markus Y. Mapara, MD, PhD, Chandra Belani, MD, David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2006) 108 (11): 507.

https://doi.org/10.1182/blood.V108.11.507.507

Published: 2006

Journal Articles

The CCR1 Antagonist BX470 Inhibits the Growth of Multiple Myeloma (MM) Cells That Produce MIP-1α.

Suzanne Lentzsch, MD, PhD, Gulsum Anderson, PhD, Li Cuiling, PhD, Horuk Richard, PhD, Markus Y. Mapara, MD, PhD, Ghobrial Irene, MD, David G. Roodman, MD, PhD

Blood (2005) 106 (11): 3383.

https://doi.org/10.1182/blood.V106.11.3383.3383

Published: 2005

Journal Articles

Thalidomide Derivative CC-4047 Inhibits Osteoclast Formation by down Regulation of PU.1.

Suzanne Lentzsch, MD, PhD, Gulsum Anderson, PhD, Noriyoshi Kurihara, DDS, PhD, Tadashi Honjo, DDS, PhD, Judith Anderson, Markus Y. Mapara, MD, PhD, David Stirling, PhD, David Roodman, MD, PhD

Blood (2005) 106 (11): 629.

https://doi.org/10.1182/blood.V106.11.629.629

Published: 2005

Journal Articles

Combination of Proteasome Inhibitor PS 341 (Velcade®) with Histone Acetylase Inhibitor (HDAC) PXD 101 Shows Superior Anti-Myeloma Activity and Inhibits Osteoclastogenesis.

Suzanne Lentzsch, MD, PhD, Gulsum Anderson, PhD, Cuiling Li, PhD, Chandra P. Belani, MD, Markus Y. Mapara, MD, PhD, David Roodman, MD, PhD

Blood (2005) 106 (11): 2488.

https://doi.org/10.1182/blood.V106.11.2488.2488

Published: 2005

NARROW

SDX-308, a Structural Analog of Etodolac, Inhibits NF-κB Activity Resulting in Significant Inhibition of Osteoclast Formation/Activity and Multiple Myeloma Cell Growth.

Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101 Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of Multiple Myeloma Growth In Vitro and In Vivo .

The CCR1 Antagonist BX470 Inhibits the Growth of Multiple Myeloma (MM) Cells That Produce MIP-1α.

Thalidomide Derivative CC-4047 Inhibits Osteoclast Formation by down Regulation of PU.1.

Combination of Proteasome Inhibitor PS 341 (Velcade®) with Histone Acetylase Inhibitor (HDAC) PXD 101 Shows Superior Anti-Myeloma Activity and Inhibits Osteoclastogenesis.

Email alerts

ASH Publications

American Society of Hematology

SDX-308, a Structural Analog of Etodolac, Inhibits NF-κB Activity Resulting in Significant Inhibition of Osteoclast Formation/Activity and Multiple Myeloma Cell Growth.

Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101 Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of Multiple Myeloma Growth In Vitro and In Vivo .

The CCR1 Antagonist BX470 Inhibits the Growth of Multiple Myeloma (MM) Cells That Produce MIP-1α.

Thalidomide Derivative CC-4047 Inhibits Osteoclast Formation by down Regulation of PU.1.

Combination of Proteasome Inhibitor PS 341 (Velcade®) with Histone Acetylase Inhibitor (HDAC) PXD 101 Shows Superior Anti-Myeloma Activity and Inhibits Osteoclastogenesis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only